الفهرس 
Bonchial asthmaOnly 14 pages are availabe for public view
 |  | from | 201 |  |  |
| | | from | 201 | | |
Abstract
Bronchial asthma is a chronic disorder characterized by airway inflammation, reversible airway obstruction, mucus hypersecretion, and airway hyper-responsiveness.(1) COPD is characterized by an airflow limitation that is not fully reversible, progressive and associated with an abnormal inflammatory response of the lungs to noxious agents.(3) LXA4 mediators are derived from the sequential actions of lipoxygenase enzymes and can inhibit chemotaxis, formation of superoxides, and generation of pro-inflammatory cytokines (e.g, IL12, and IL5) by neutrophils, eosinophils. (7,8) The aim of the study is to evaluate role of LXA4 as anti-inflammatory mediator in bronchial asthma and COPD. The present study included 90 subjects divided into 39 patients with controlled bronchial asthma, 39 patients with stable COPD, and 12 healthy subjects. They were selected from Menoufia University Hospital from January 2017 to August 2017. Current study demonstrated that as regard age and BMI, there was significant difference between asthma, COPD and normal healthy subjects, while there was no significant difference as regard sex. Current study demonstrated that there was significant difference between three studied groups as regard blood eosinophilic %, and neutrophilic %. As regard eosinophilic % and neutrophilic%, current study demonstrated that severe asthma subgroup was significantly higher than moderate and mild asthma subgroups.
Current study showed that as regard eosinophilic %, there was no statistically significant difference between COPD subgroups, while as regard neutrophilic %, severe COPD group was significantly higher than both mild and moderate subgroups. Current study demonstrated that as regard serum LXA4 level, It was statistically significantly higher in bronchial asthma group than COPD group and control group. While, there was no significant difference between COPD group and normal subjects group. As regard comparing serum LXA4 in asthma subgroups, current study showed that serum LXA4 was statistically significantly higher in mild asthma subgroup than moderate and severe subgroups. Current study demonstrated that there was no significant difference between COPD subgroups as regard serum LXA4. According to LXA4 correlations in asthma group, current study demonstrated that serum LXA4 significantly correlated positively with FEV1, FEV1 % of predicted and FEV1/FVC ratio, and significantly correlated inversely with blood eosinophilic % and neutrophilic%. According to serum LXA4 correlations in COPD group, current study demonstrated that LXA4 significantly correlated inversely with blood neutrophilic %.